{"doi":"10.1097/coc.0000000000000052","title":"Meningioma in Breast Cancer Patients","abstract":"<jats:sec>\n            <jats:title>Objectives:</jats:title>\n            <jats:p>Although an association between meningioma and breast cancer (BC) has been postulated, clear mechanisms remain obscure. By conducting population-based analyses in women with both BC and meningioma, hypothesis-generating causal links were pursued.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods:</jats:title>\n            <jats:p>Using the US SEER 18 registry (2004 to 2009), clinicopathologic and demographic characteristics from cohorts of women with only BC (n=279,821) or meningioma (n=19,570) diagnoses were compared with 412 women with both diagnoses (BC-meningioma).</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Results:</jats:title>\n            <jats:p>BC diagnosis preceded meningioma by &gt;2 months in 48% of women; 20% had synchronous (within 2 mo) disease. Median meningioma size was 1.9 and 2.4 cm in the BC-meningioma and meningioma cohorts, respectively (<jats:italic toggle=\"yes\">P</jats:italic>=0.0009). Among BC-meningioma patients, meningioma size was similar whether diagnosed &gt;2 months prior, synchronously, or &gt;2 months after BC. Meningioma was pathologically confirmed in 38% of BC-meningioma and 51% of meningioma patients. Distribution of BC histologies was comparable in patients with and without meningioma, with ductal type predominating (80% in BC-meningioma, 83% in BC). Although hormone receptor status of invasive BC was not significantly different between BC-meningioma and BC groups, the BC-meningioma cohort had fewer women with ER+/PR+ in situ disease (<jats:italic toggle=\"yes\">P</jats:italic>=0.006). BC stage among women with meningioma was more advanced versus women with BC only.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:</jats:title>\n            <jats:p>Women with BC and meningioma have smaller-sized meningiomas and more advanced BCs compared with women having only 1 diagnosis. As there was no temporal relationship between size and latency between tumor diagnoses, the disparity in meningioma size between BC-meningioma and meningioma cohorts may have BC-associated biological components that warrant further study.</jats:p>\n          </jats:sec>","journal":"American Journal of Clinical Oncology","year":2017,"id":592968,"datarank":1.0934091887625788,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.6684271871541463,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.6684271871541463,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":16,"citers_with_citation_signal":12,"citers_with_endowment":12,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1138816,"name":"Craig E. Grossman","orcid":null,"position":1,"is_corresponding":false},{"id":241746,"name":"Michael T. Milano","orcid":"0000-0001-8676-2855","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Meningioma in Breast Cancer Patients","abstract":"<jats:sec>\n            <jats:title>Objectives:</jats:title>\n            <jats:p>Although an association between meningioma and breast cancer (BC) has been postulated, clear mechanisms remain obscure. By conducting population-based analyses in women with both BC and meningioma, hypothesis-generating causal links were pursued.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods:</jats:title>\n            <jats:p>Using the US SEER 18 registry (2004 to 2009), clinicopathologic and demographic characteristics from cohorts of women with only BC (n=279,821) or meningioma (n=19,570) diagnoses were compared with 412 women with both diagnoses (BC-meningioma).</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Results:</jats:title>\n            <jats:p>BC diagnosis preceded meningioma by &gt;2 months in 48% of women; 20% had synchronous (within 2 mo) disease. Median meningioma size was 1.9 and 2.4 cm in the BC-meningioma and meningioma cohorts, respectively (<jats:italic toggle=\"yes\">P</jats:italic>=0.0009). Among BC-meningioma patients, meningioma size was similar whether diagnosed &gt;2 months prior, synchronously, or &gt;2 months after BC. Meningioma was pathologically confirmed in 38% of BC-meningioma and 51% of meningioma patients. Distribution of BC histologies was comparable in patients with and without meningioma, with ductal type predominating (80% in BC-meningioma, 83% in BC). Although hormone receptor status of invasive BC was not significantly different between BC-meningioma and BC groups, the BC-meningioma cohort had fewer women with ER+/PR+ in situ disease (<jats:italic toggle=\"yes\">P</jats:italic>=0.006). BC stage among women with meningioma was more advanced versus women with BC only.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:</jats:title>\n            <jats:p>Women with BC and meningioma have smaller-sized meningiomas and more advanced BCs compared with women having only 1 diagnosis. As there was no temporal relationship between size and latency between tumor diagnoses, the disparity in meningioma size between BC-meningioma and meningioma cohorts may have BC-associated biological components that warrant further study.</jats:p>\n          </jats:sec>","is_dataset_classified":null,"base_score":2.833213344056216,"endowment":2.833213344056216,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24577166","pmcid":null,"openalex_id":"https://openalex.org/W1982741417","authors":[],"funders":[],"total_grants":0,"fwci":1.0659,"citation_percentile":0.7654273,"influential_citations":0,"citation_trend":[{"year":2015,"count":2},{"year":2017,"count":3},{"year":2018,"count":1},{"year":2019,"count":1},{"year":2020,"count":1},{"year":2021,"count":4},{"year":2022,"count":1},{"year":2023,"count":2},{"year":2024,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://journals.lww.com/00000421-201702000-00002","host_type":"publisher"},{"url":"https://doi.org/10.1097/coc.0000000000000052","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/24577166","host_type":"repository"}],"fields_of_study":["Meningioma and schwannoma management","Brain Metastases and Treatment","Glioma Diagnosis and Treatment"],"mesh_terms":["Adult","Aged","Aged, 80 and over","Breast Neoplasms","Female","Humans","Meningeal Neoplasms","Meningioma","Middle Aged","Neoplasms, Multiple Primary","Retrospective Studies","Cohort Studies"],"keywords":["Meningioma","Medicine","Breast cancer","Cohort","Malignant meningioma","Internal medicine","Cancer","Radiology","Oncology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-26T16:28:41.937402Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}